Copyright Reports & Markets. All rights reserved.

Global Dual Isotope Radionuclide Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Dual Isotope Radionuclide Therapy
  • 1.2 Classification of Dual Isotope Radionuclide Therapy by Type
    • 1.2.1 Overview: Global Dual Isotope Radionuclide Therapy Market Size by Type: 2025 Versus 2031
    • 1.2.2 Global Dual Isotope Radionuclide Therapy Revenue Market Share by Type in 2031
    • 1.2.3 β⁻ + α
    • 1.2.4 β⁻ + Auger Electrons
    • 1.2.5 α + Integrated Diagnosis and Treatment
  • 1.3 Global Dual Isotope Radionuclide Therapy Market by Application
    • 1.3.1 Overview: Global Dual Isotope Radionuclide Therapy Market Size by Application: 2025 Versus 2031
    • 1.3.2 Clinical Trial Stage
    • 1.3.3 Preclinical
    • 1.3.4 Laboratory Proof of Concept
  • 1.4 Global Dual Isotope Radionuclide Therapy Market Size & Forecast
  • 1.5 Market Drivers, Restraints and Trends
    • 1.5.1 Dual Isotope Radionuclide Therapy Market Drivers
    • 1.5.2 Dual Isotope Radionuclide Therapy Market Restraints
    • 1.5.3 Dual Isotope Radionuclide Therapy Trends Analysis

2 Company Profiles

  • 2.1 EANM
    • 2.1.1 EANM Details
    • 2.1.2 EANM Major Business
    • 2.1.3 EANM Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.1.4 EANM Recent Developments and Future Plans
  • 2.2 MSKCC
    • 2.2.1 MSKCC Details
    • 2.2.2 MSKCC Major Business
    • 2.2.3 MSKCC Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.2.4 MSKCC Recent Developments and Future Plans
  • 2.3 Peter MacCallum
    • 2.3.1 Peter MacCallum Details
    • 2.3.2 Peter MacCallum Major Business
    • 2.3.3 Peter MacCallum Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.3.4 Peter MacCallum Recent Developments and Future Plans
  • 2.4 Bayer
    • 2.4.1 Bayer Details
    • 2.4.2 Bayer Major Business
    • 2.4.3 Bayer Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.4.4 Bayer Recent Developments and Future Plans
  • 2.5 Novartis
    • 2.5.1 Novartis Details
    • 2.5.2 Novartis Major Business
    • 2.5.3 Novartis Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.5.4 Novartis Recent Developments and Future Plans
  • 2.6 Fusion Pharmaceuticals
    • 2.6.1 Fusion Pharmaceuticals Details
    • 2.6.2 Fusion Pharmaceuticals Major Business
    • 2.6.3 Fusion Pharmaceuticals Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.6.4 Fusion Pharmaceuticals Recent Developments and Future Plans
  • 2.7 ITM Isotope Technologies Munich
    • 2.7.1 ITM Isotope Technologies Munich Details
    • 2.7.2 ITM Isotope Technologies Munich Major Business
    • 2.7.3 ITM Isotope Technologies Munich Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.7.4 ITM Isotope Technologies Munich Recent Developments and Future Plans
  • 2.8 Actinium Pharmaceuticals
    • 2.8.1 Actinium Pharmaceuticals Details
    • 2.8.2 Actinium Pharmaceuticals Major Business
    • 2.8.3 Actinium Pharmaceuticals Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.8.4 Actinium Pharmaceuticals Recent Developments and Future Plans
  • 2.9 SmartNuclide
    • 2.9.1 SmartNuclide Details
    • 2.9.2 SmartNuclide Major Business
    • 2.9.3 SmartNuclide Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.9.4 SmartNuclide Recent Developments and Future Plans
  • 2.10 Sinotau Pharmaceutical Group
    • 2.10.1 Sinotau Pharmaceutical Group Details
    • 2.10.2 Sinotau Pharmaceutical Group Major Business
    • 2.10.3 Sinotau Pharmaceutical Group Dual Isotope Radionuclide Therapy Product and Solutions
    • 2.10.4 Sinotau Pharmaceutical Group Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Dual Isotope Radionuclide Therapy Revenue and Share by Players (2025 & 2031)
  • 3.2 Dual Isotope Radionuclide Therapy Players Head Office, Products and Services Provided
  • 3.3 Dual Isotope Radionuclide Therapy Mergers & Acquisitions
  • 3.4 Dual Isotope Radionuclide Therapy New Entrants and Expansion Plans

4 Global Dual Isotope Radionuclide Therapy Forecast by Region

  • 4.1 Global Dual Isotope Radionuclide Therapy Market Size by Region: 2025 VS 2031
  • 4.2 Global Dual Isotope Radionuclide Therapy Market Size by Region, (2025-2031)
  • 4.3 North America
    • 4.3.1 Key Companies of Dual Isotope Radionuclide Therapy in North America
    • 4.3.2 Current Situation and Forecast of Dual Isotope Radionuclide Therapy in North America
    • 4.3.3 North America Dual Isotope Radionuclide Therapy Market Size and Prospect (2025-2031)
  • 4.4 Europe
    • 4.4.1 Key Companies of Dual Isotope Radionuclide Therapy in Europe
    • 4.4.2 Current Situation and Forecast of Dual Isotope Radionuclide Therapy in Europe
    • 4.4.3 Europe Dual Isotope Radionuclide Therapy Market Size and Prospect (2025-2031)
  • 4.5 Asia-Pacific
    • 4.5.1 Key Companies of Dual Isotope Radionuclide Therapy in Asia-Pacific
    • 4.5.2 Current Situation and Forecast of Dual Isotope Radionuclide Therapy in Asia-Pacific
    • 4.5.3 Asia-Pacific Dual Isotope Radionuclide Therapy Market Size and Prospect (2025-2031)
    • 4.5.4 China
    • 4.5.5 Japan
    • 4.5.6 South Korea
  • 4.6 South America
    • 4.6.1 Key Companies of Dual Isotope Radionuclide Therapy in South America
    • 4.6.2 Current Situation and Forecast of Dual Isotope Radionuclide Therapy in South America
    • 4.6.3 South America Dual Isotope Radionuclide Therapy Market Size and Prospect (2025-2031)
  • 4.7 Middle East & Africa
    • 4.7.1 Key Companies of Dual Isotope Radionuclide Therapy in Middle East & Africa
    • 4.7.2 Current Situation and Forecast of Dual Isotope Radionuclide Therapy in Middle East & Africa
    • 4.7.3 Middle East & Africa Dual Isotope Radionuclide Therapy Market Size and Prospect (2025-2031)

5 Market Size Segment by Type

  • 5.1 Global Dual Isotope Radionuclide Therapy Market Forecast by Type (2025-2031)
  • 5.2 Global Dual Isotope Radionuclide Therapy Market Share Forecast by Type (2025-2031)

6 Market Size Segment by Application

  • 6.1 Global Dual Isotope Radionuclide Therapy Market Forecast by Application (2025-2031)
  • 6.2 Global Dual Isotope Radionuclide Therapy Market Share Forecast by Application (2025-2031)

7 Research Findings and Conclusion

    8 Appendix

    • 8.1 Methodology
    • 8.2 Research Process and Data Source

    According to our latest research, the global Dual Isotope Radionuclide Therapy market size will reach USD 15.6 million in 2031, growing at a CAGR of 12.7% over the analysis period.
    Dual isotope radionuclide therapy is a strategy that uses two different radionuclides to treat diseases (especially cancer) in combination, improving the therapeutic effect and reducing side effects by combining the physical and biological properties of different nuclides. Dual-nuclide therapy represents an important direction in precision radiation medicine, especially for complex or metastatic cancers.

    This report is a detailed and comprehensive analysis for global Dual Isotope Radionuclide Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Dual Isotope Radionuclide Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Dual Isotope Radionuclide Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Dual Isotope Radionuclide Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Dual Isotope Radionuclide Therapy market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Dual Isotope Radionuclide Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Dual Isotope Radionuclide Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include EANM, MSKCC, Peter MacCallum, Bayer, Novartis, Fusion Pharmaceuticals, ITM Isotope Technologies Munich, Actinium Pharmaceuticals, SmartNuclide, Sinotau Pharmaceutical Group, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Dual Isotope Radionuclide Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    β⁻ + α
    β⁻ + Auger Electrons
    α + Integrated Diagnosis and Treatment
    Market segment by Application
    Clinical Trial Stage
    Preclinical
    Laboratory Proof of Concept
    Market segment by players, this report covers
    EANM
    MSKCC
    Peter MacCallum
    Bayer
    Novartis
    Fusion Pharmaceuticals
    ITM Isotope Technologies Munich
    Actinium Pharmaceuticals
    SmartNuclide
    Sinotau Pharmaceutical Group
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Dual Isotope Radionuclide Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Dual Isotope Radionuclide Therapy, with revenue, gross margin, and global market share of Dual Isotope Radionuclide Therapy from 2020 to 2025.
    Chapter 3, the Dual Isotope Radionuclide Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Dual Isotope Radionuclide Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Dual Isotope Radionuclide Therapy.
    Chapter 13, to describe Dual Isotope Radionuclide Therapy research findings and conclusion.

    Buy now